← ANALYST RATINGS · TIPRANKS
BridgeBio Pharma (BBIO): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy1 Hold0 Sell
Ratings of 14 analysts in the last 3 months · top analysts only12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $107, the highest $130, the lowest $92.00. The average is +61.4% from the last price of $66.39.
Analyst ratings 24
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $102 | Buy | +53.6% | Reiterated | 15.10.26on TipRanks 07:30 | +3.1%next day 0.0% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $82.00 → $92.00+12.2% | Buy | +38.6% | Reiterated | 14.10.26on TipRanks 19:50 | +3.1%next day 0.0% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $120 | Buy | +80.8% | Reiterated | 14.10.26on TipRanks 11:35 | +3.7%next day +3.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $67.00 → $66.00−1.5% | Hold | −0.6% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $70.00 → $69.00−1.4% | Hold | +3.9% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $65.00 → $66.00+1.5% | Hold | −0.6% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $65.00 → $66.00+1.5% | Hold | −0.6% | Reiterated | 11.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $67.00 → $66.00−1.5% | Hold | −0.6% | Reiterated | 10.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $66.00 → $65.00−1.5% | Hold | −2.1% | Reiterated | 10.10.26on TipRanks 02:05 | — | |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $100 | Buy | +50.6% | Reiterated | 08.10.26on TipRanks 21:45 | −0.1%next day +0.7% · 5 days +3.6% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $157 → $156−0.6% | Buy | +135.0% | Reiterated | 07.10.26on TipRanks 03:55 | −0.4%next day −1.8% · 5 days −1.4% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $106 | Buy | +59.7% | Reiterated | 06.10.26on TipRanks Oct 7 08:26 | +0.7%next day −0.4% · 5 days −5.3% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $104 | Buy | +56.7% | Reiterated | 06.10.26on TipRanks Oct 7 06:45 | +0.7%next day −0.4% · 5 days −5.3% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 06.10.26on TipRanks 10:55 | +0.7%next day −0.4% · 5 days −5.3% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $110 | Buy | +65.7% | Reiterated | 24.09.26on TipRanks 07:30 | +0.9%next day −1.6% · 5 days +1.4% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $130 | Buy | +95.8% | Reiterated | 14.09.26on TipRanks 09:15 | +0.4%next day −5.1% · 5 days −9.9% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $96.00 → $110+14.6% | Buy | +65.7% | Reiterated | 31.08.26on TipRanks 10:50 | +0.3%next day +0.7% · 5 days −2.2% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $110 | Buy | +65.7% | Reiterated | 31.08.26on TipRanks 10:15 | +0.3%next day +0.7% · 5 days −2.2% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $115 | Buy | +73.2% | Reiterated | 31.08.26on TipRanks 07:35 | +0.3%next day +0.7% · 5 days −2.2% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $110 | Buy | +65.7% | Reiterated | 29.08.26on TipRanks Aug 31 09:35 | +0.3%next day +0.7% · 5 days −2.2% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $93.00 → $94.00+1.1% | Hold | +41.6% | Reiterated | 12.08.26on TipRanks 06:55 | −0.1%next day −3.8% · 5 days +0.6% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $100 → $111+11.0% | Buy | +67.2% | Assigned | 12.08.26on TipRanks Aug 11 10:16 | −0.8%next day −0.1% · 5 days −0.5% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $102 → $107+4.9% | Buy | +61.2% | Reiterated | 12.08.26on TipRanks Aug 11 08:45 | −0.8%next day −0.1% · 5 days −0.5% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $98.00 → $97.00−1.0% | Buy | +46.1% | Reiterated | 11.08.26on TipRanks 07:20 | −0.8%next day −0.1% · 5 days −0.5% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $98.00 → $102+4.1% | Buy | +53.6% | Reiterated | 11.08.26on TipRanks 06:55 | −0.8%next day −0.1% · 5 days −0.5% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $125 → $98.00−21.6% | Buy | +47.6% | Reiterated | 17.06.26on TipRanks 06:35 | +2.4%next day −2.7% · 5 days +4.1% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $100 → $114+14.0% | Buy | +71.7% | Reiterated | 08.05.26on TipRanks 07:55 | −0.9%next day −4.2% · 5 days −2.1% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $112 → $116+3.6% | Buy | +74.7% | Reiterated | 08.05.26on TipRanks 07:50 | −0.9%next day −4.2% · 5 days −2.1% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $75.00 → $86.00+14.7% | Buy | +29.5% | Reiterated | 15.12.25on TipRanks 09:30 | −0.7%next day +1.9% · 5 days +2.6% | ↗ |
| Unknown Analyst | Roth MKM | $73.00 → $81.00+11.0% | Buy | +22.0% | Reiterated | 30.10.25on TipRanks 08:20 | −3.8%next day −1.5% · 5 days +0.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering BridgeBio Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $111 at a price of $66.14 (+68.5%); now: $110 at $66.39 (+66.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 1 | 4 | 9 |
| Buy | 22 | 16 | 18 | 22 | 19 | 15 |
| Hold | 4 | 5 | 6 | 3 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.57 (from $-0.81 to $-0.28). Last quarter: $-0.78.
Sales
Next quarter’s sales estimate — $281M (from $248M to $347M). Last quarter: $244M.
Best top-analyst consensus in the sector · Healthcare
About BridgeBio Pharma
- CEO: Neil Kumar
- Employees: 999
- 3160 Porter Drive, Palo Alto, CA, 94304, US
- www.bridgebio.com
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Data from the stock’s TipRanks forecast page, read 41 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗